Oxygenta Pharmaceutical Ltd - Stock Valuation and Financial Performance

BSE: 524636 | NSE: | Pharmaceuticals & Drugs | Small Cap

Oxygenta Pharma Share Price

30.65 0.02 0.07%
as on 12-Jul'24 16:01

DeciZen - make an informed investing decision on Oxygenta Pharma

Overall Rating
M-Cap below 500cr. High Risk from low Liquidity Bole Toh

1. Quality

2. Valuation

Fair

3. Price Trend

Oxygenta Pharmaceutical stock performance -

mw4me loader
P/E Ratio (SA):
0.00
Market Cap:
109.5 Cr.
52-wk low:
25
52-wk high:
52.3

Is Oxygenta Pharmaceutical Ltd an attractive stock to invest in?

1. Is Oxygenta Pharmaceutical Ltd a good quality company?

Past 10 year’s financial track record analysis by Moneyworks4me indicates that Oxygenta Pharmaceutical Ltd is a below average quality company.

2. Is Oxygenta Pharmaceutical Ltd undervalued or overvalued?

The key valuation ratios of Oxygenta Pharmaceutical Ltd's currently when compared to its past seem to suggest it is in the Fair zone.

3. Is Oxygenta Pharmaceutical Ltd a good buy now?

The Price Trend analysis by MoneyWorks4Me indicates it is Weak which suggest that the price of Oxygenta Pharmaceutical Ltd is likely to Fall in the short term. However, please check the rating on Quality and Valuation before investing.

10 Year X-Ray of Oxygenta Pharma:

Analysis of Financial Track Record

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.

Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.
Oxygenta Pharmaceutical Ltd has not performed well majority of the past ten years indicating its past ten year financial track record is not good

Value Creation

Value Creation Index Colour Code Guide

Mar'14Mar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23TTM
ROCE % -191.7%18,928.8%183.1%87.4%37.3%21.4%58.2%-200.7%4.4%-50.6%-
Value Creation
Index
NANANANANANANA-15.3NANA-

Growth Parameters

Growth Parameters Colour Code Guide

Sales 2.56.212.48.212.920.513.75260.53140
Sales YoY Gr.-152.6%99.2%-34.4%57.9%59.4%-33.1%279.2%16.3%-48.8%-
Adj EPS -4.2-6-5.4-5.7-4.4-3.2-8.42.9-0-7.7-1
YoY Gr.-NANANANANANANA-101.1%NA-
BVPS (₹) -9.1-15.8-21.1-26.8-31.3-34.5-40.1-37.3-24.4-32.5-5
Adj Net
Profit
-4.3-6.1-5.5-5.8-4.5-3.3-8.62.90-11-3
Cash Flow from Ops. -2.7-4.30.90.51.3-7.8-2.6-1.6-1.7-1.6-
Debt/CF from Ops. -3.9-3.420.63714.9-2.9-10.4-29.5-31-41.6-

CAGR

CAGR Colour Code Guide

9 Years 5 Years 3 Years 1 Years
Sales 32.5%19.2%31.2%-48.8%
Adj EPS NANANANA
BVPSNANANANA
Share Price 15.6% 30.6% 61.3% -28.6%

Key Financial Parameters

Performance Ratio Colour Code Guide

Mar'14Mar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23TTM
Return on
Equity %
60.148.329.223.715.39.722.5-7.40.127.25.2
Op. Profit
Mgn %
-140.2-66.1-33.5-59.4-31.1-10-57.47.42.4-23-24.4
Net Profit
Mgn %
-173.6-98-44.3-71.2-35.2-15.9-62.55.6-0.1-35.4-8.8
Debt to
Equity
-1.2-0.9-0.8-0.7-0.6-0.6-0.7-1.3-1.5-1.5-
Working Cap
Days
2682561942901511222168282217107
Cash Conv.
Cycle
-481-264-247-229-154-75-14-11052-22

Recent Performance Summary

Sales growth is growing at healthy rate in last 3 years 31.21%

Sales growth is good in last 4 quarters at 34.60%

Return on Equity has declined versus last 3 years average to 5.20%

Latest Financials - Oxygenta Pharmaceutical Ltd.

Standalone Consolidated
TTM EPS (₹) -1 -
TTM Sales (₹ Cr.) 39.6 -
BVPS (₹.) -5 -
Reserves (₹ Cr.) -53 -
P/BV -6.24 -
PE 0.00 -
From the Market
52 Week Low / High (₹) 25.02 / 52.27
All Time Low / High (₹) 0.10 / 52.27
Market Cap (₹ Cr.) 109
Equity (₹ Cr.) 35.5
Face Value (₹) 10
Industry PE 43.9

Management X-Ray of Oxygenta Pharma:

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged *0.000.000.000.000.000.000.000.000.000.00
* Pledged shares as % of Promoter's holding (%)

Event Update

Login/Register to view analysis.

Analyst's Notes

Key Ratios of Oxygenta Pharma

Adj EPS (Rs.)

Sales (Cr.)

ROE (%)

ROCE (%)

Profit And Loss

(All Figures are in Crores.)
PARTICULARSMar'14Mar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23
Sales26128132114526131
Operating Expenses 6101713172322485938
Manufacturing Costs23333226912
Material Costs0286101616374723
Employee Cost 2333332411
Other Costs 2222111222
Operating Profit -3-4-4-5-4-2-841-7
Operating Profit Margin (%) -140.0%-66.1%-33.5%-59.4%-31.1%-10.0%-57.4%7.4%2.4%-23.0%
Other Income 0001100000
Interest 0011111211
Depreciation 1311111122
Exceptional Items 000000421-1
Profit Before Tax -4-7-6-6-4-3-630-11
Tax 0-100000000
Profit After Tax -4-6-5-6-5-3-63-1-12
PAT Margin (%) -173.0%-98.0%-44.3%-71.2%-35.2%-15.9%-42.2%5.6%-1.0%-37.3%
Adjusted EPS (₹)-4.2-6.0-5.4-5.7-4.4-3.2-5.72.9-0.4-8.2
Dividend Payout Ratio (%)0%0%0%0%0%0%0%0%0%0%

Balance Sheet

(All Figures are in Crores.)
PARTICULARSMar'14Mar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23

Equity and Liabilities

Shareholders Fund -9-16-22-27-32-35-41-38-35-46
Share Capital 10101010101010101414
Reserves -19-26-32-38-42-45-51-48-49-60
Minority Interest0000000000
Debt11141718182126485268
Long Term Debt11141718182125455163
Short Term Debt0000000315
Trade Payables911159119814624
Others Liabilities 8810192026261079
Total Liabilities 18182019172119343154

Fixed Assets

Gross Block24212323242525313646
Accumulated Depreciation891011121314151619
Net Fixed Assets16121312121211162028
CWIP 0000000100
Investments 0000000000
Inventories011225412712
Trade Receivables11110102210
Cash Equivalents 0000000000
Others Assets2543332324
Total Assets 18182019172119343154

Cash Flow

(All Figures are in Crores.)
PARTICULARSMar'14Mar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23
Cash Flow From Operating Activity -3-4111-8-3-2-2-2
PBT -4-7-6-6-4-3-630-11
Adjustment 1311222334
Changes in Working Capital 1-0554-61-8-46
Tax Paid 0000000000
Cash Flow From Investing Activity -21-2-10-10-7-5-10
Capex -2-2-2-10-1-1-7-5-10
Net Investments 0000000000
Others 0300000000
Cash Flow From Financing Activity 4310-1839611
Net Proceeds from Shares 0000000040
Net Proceeds from Borrowing 442109410313
Interest Paid 00-1-1-1-1-1-2-1-1
Dividend Paid 0000000000
Others 0000000000
Net Cash Flow -1000000000
PARTICULARSMar'14Mar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23
Ratios
ROE (%)N/AN/AN/AN/AN/AN/AN/AN/AN/AN/A
ROCE (%)N/AN/AN/AN/AN/AN/AN/AN/AN/AN/A
Asset Turnover Ratio0.140.340.660.420.711.080.691.981.860.73
PAT to CFO Conversion(x)N/AN/AN/AN/AN/AN/AN/A-0.67N/AN/A
Working Capital Days
Receivable Days904431531991271069
Inventory Days516216349611285758112
Payable Days9,9831,62258479036822420010978235

Oxygenta Pharmaceutical Ltd Stock News

Oxygenta Pharmaceutical Ltd FAQs

Company share prices are keep on changing according to the market conditions. The closing price of Oxygenta Pharma on 12-Jul-2024 16:01 is ₹30.65.
Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 12-Jul-2024 16:01 the market cap of Oxygenta Pharma stood at ₹109.5.
The latest P/E ratio of Oxygenta Pharma as of 12-Jul-2024 16:01 is 0.00.
The latest P/B ratio of Oxygenta Pharma as of 12-Jul-2024 16:01 is -6.24.
The 52-week high of Oxygenta Pharma is ₹52.27 and the 52-week low is ₹25.02.
The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Oxygenta Pharma is ₹39.64 ( Cr.) .

About Oxygenta Pharmaceutical Ltd

SS Organics was incorporated in 1990, is a pharmaceutical company involved in the manufacture and marketing of bulk drugs and intermediates.

A wide range of new generation quinolones, antiasthmatic, antiulcerant, and anti-inflammatory drugs are manufactured. The product range also includes omeprazole, rabeprazole sodium, lansoprazole, esomeprazole magnesium trihydrate, non-pariel seeds, pantoprazole pellets, diclofenac sodium pellets, gabapentior, mooxafloxacin, ramipril, atorvastatin, and voriconazole.

Designed and built as per US FDA standards for production of bulk drugs and custom synthesis of intermediates, the plant located in the Medak district of Andhra Pradesh has an installed capacity 320 TPA. Major export destinations include Europe, USA, South America, and Asia Pacific Region. It reaches the America markets through its subsidiary based in Maryland, USA.

The registered office is at Survey No 252/1, Aroor Village, Sadasivapet Mandal, Medak, Andhra Pradesh.

Read More Read Less
You have 2 views remaining as a Guest User. To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login Now
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt.Ltd.